Stream

William Domburg

Discussion  - 
 
TC.To

Fair Value: CAD28
Actually overvalued
Average yearly return: 61%  
Outperformer
A BUY around CAD22
1
Add a comment...

William Domburg

Discussion  - 
 
What a day for our blog portfolio:

Portfolio value: €35,891.61
Day's gain: +795.73 (2.27%)
Overall return: 29.53%
1
Add a comment...

William Domburg

Discussion  - 
 
Analysts Disagree Over Significance of Akorn, Inc.’s Financial Errors (AKRX)
April 28, 2015 7:30 AM EDT in Contributor Opinions • Industrial
Akorn, Inc. (NASDAQ:AKRX) announced on Friday that it will have to restate financials from 2014 due to accounting errors. Akorn warned that their financial reports for 2014, filed by KMPG, should not be relied upon. Though the pharmaceutical company affirmed its 2015 earnings per share guidance, the stock fell by more than 20% on Monday following the announcement.

Akorn identified the 2014 accounting missteps when reviewing financials for the first quarter of 2015. The miscalculations stemmed from understatements of rebates and other sales allowances. Though the company is still determining the exact impact of the miscalculations, initial estimates believe the errors resulted in a $20 million to $35 million overstatement of net revenue and pre-tax income for the full-year 2014.

Consequently, Akorn warned investors that it does not expect to file its quarterly report by the SEC deadline. However, Akorn affirmed guidance for 2015 earnings, expecting to post adjusted diluted EPS between $1.88 and $1.98.

On April 27, Akorn announced recent executive appointments including Randall Pollard who was appointed Corporate Controller. In this role, Pollard will oversee all accounting and financial reporting.

Analysts weighed in on the impact the flawed accounting will have on the pharmaceutical company.

On Monday, analyst David Steinberg reaffirmed a Buy rating on Akorn, though he did not provide a price target. Steinberg does not think the accounting errors will have a significant impact on the stock. He has rated Akorn once before on April 20, when he set a $56 price target for the stock. He was bullish on Akorn because he believed its clobetasol cream was more successful than that of Actavis’s.

Since David Steinberg has only rated Akorn once before on April 20, he has a 100% success rate recommending the stock with a +1% average return. Overall, David Steinberg has an 81% success rate recommending stocks with a +24.5% average return per rating.

Separately, analyst David Amsellem of Piper Jaffray downgraded Akorn from Overweight to Neutral with a price target of $53. Amsellem commented, “Though management does not believe the accounting issues will impact 1Q15 results, and it is sticking with its 2015 guidance, there is in our view far too large of a credibility gap to simply take those statements at face value.” Amsellem believes the company has lost credibility to the point that Akorn must replace its CFO.

David Amsellem has rated Akorn four times since July 2012, earning a 67% success rate recommending the company with a +25% average return per AKRX rating. Overall, Amsellem has an 80% success rate recommending stocks with a +23.7% average return per recommendation.

On average, the top analyst recommendation for Akorn on TipRanks is Hold.
1
Add a comment...

Curt Dalton

Discussion  - 
Apple Watch Parts Failure and Demand Downgrade From UBS, Now What For Apple? On Thursday, US markets were down significantly, bringing April to a close on a negative note. Technology stocks were responsible for much of the downdraft, including weaknesses in such bellwethers as Apple, Google and IBM.
1
Add a comment...
 
As many of you already know it takes a lot of time to do the fundamental research on a company. So we have done it all for you. This report will give you the company background, the leadership, earnings, opportunities, the competitors and what the analysts think.

With this information you can decide whether this is a company that you are interested in investing in and then go take a look at the charts and plan your trade!
  
http://hotstocksforincome.com/veeva-hot-stock-report/
1
Add a comment...

Curt Dalton

Stock Analysis  - 
Is Amazon's Cloud Service About To Remake The Whole AMZN Stock Price? On Friday, US stocks were up moderately, led by gains in the utilities, consumer services and technology sectors. The Dow Jones Industrial Average was up by 0.12%, and the S&P 500 climbed by 0.23%.
1
Add a comment...
 
Dear Traders,


How do you spot the KPP's (Key Pivot Points)?


Watch This short Video on KPP's
https://www.youtube.com/watch?v=-Lelgv_q7qE&feature=youtu.be
1
Add a comment...

Curt Dalton

Discussion  - 
Netflix Decides To Go International And The Shares Take Flight - On Wednesday, stock prices in New York rose on the back of strong earnings results from a number of key companies.
1
Add a comment...
 
Know the stocks your in, learn more about Fibonacci Retracements.
Watch This short Video on Fibonacci Retracements
https://www.youtube.com/watch?v=vxXz2x6B51A&feature=youtu.be
1
Add a comment...

About this community

An investment community aimed to help the average investor understand the stock market. Ideas, reports, discussions and more. If you need or want a public company to be analyzed just drop a comment under the "Request of New Analysis" section and we'll try to get it to you in a timely manner.

Fernando MB

Stock Analysis  - 
 
05-19-2015 TRADING IDEA $LNKD LAST PRICE 194.65 NEW TRADING ASISTANCE  REAL TIME. Hi mates how you doing. i started this month a new service for clients and investors. The service includes my trading ops in real time. buy lim...
1
Add a comment...

Curt Dalton

Discussion  - 
Twitter Falls From It's Nest And SalesForce.Com Has A Secret Admirer? On Wednesday, US stock markets were broadly lower after GDP growth in Q1 came in below estimates. However, the US Federal Reserve also acknowledged that there is weakness in some sectors of the US economy, which prevented further falls in stock markets since investors now believe that interest rate rises not on the cards until at least September.
1
Add a comment...

William Domburg

Discussion  - 
 
We are bullish again on the Nasdaq.
1
Add a comment...

William Domburg

Discussion  - 
 
 10 of our goodies:

CORCEPT THERAPEUTICS INCORPORA
MONDO TV S.P.A.
CAMBREX CORP
INUVO, INC
ABIOMED
BE SEMICONDUCTOR
ADLER REAL ESTATE
PHARMACYCLICS
XING N
ORCH.KAZIBAO REGRP.
1
Add a comment...
 
www.hotstocksforincome.com


Check out our blog! Become a member.
1
Add a comment...

William Domburg

Discussion  - 
 
 
Update of our BLOG-portfolio with a 14% return since Feb 2014 on:
www.bloggen.be/wivado
1
Add a comment...

William Domburg

Discussion  - 
 
You, Canadians, can buy cheap €-stocks
1
Add a comment...

William Domburg

Discussion  - 
 
Update of our BLOG-portfolio with a 13% return since Feb 2014 on:
www.bloggen.be/wivado
Beleggen, aandelen, invest, stocks, investment, share
1
Add a comment...